The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX

被引:0
作者
Yufeng Wang
Yasuhiro Kuramitsu
Takao Kitagawa
Kazuhiro Tokuda
Byron Baron
Junko Akada
Kazuyuki Nakamura
机构
[1] Yamguchi University Graduate school of Medicine,Department of Biochemistry and Functional Proteomics
[2] Centre of Clinical Laboratories in Tokuyama Medical Association Hospital,undefined
来源
Targeted Oncology | 2015年 / 10卷
关键词
Pancreatic Cancer; Pancreatic Cancer Cell; Lenalidomide; HDAC Inhibitor; Ataxia Telangiectasia Mutate;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:575 / 581
页数:6
相关论文
共 194 条
[1]  
Mori-Iwamoto S(2007)Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine Int J Oncol 31 1345-50
[2]  
Kuramitsu Y(2008)A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines Mol Med Rep 1 429-34
[3]  
Ryozawa S(2011)KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine Chemotherapy 57 12-6
[4]  
Mikuria K(2012)Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells Anticancer Res 32 2295-9
[5]  
Fujimoto M(1991)2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase J Med Chem 34 1879-84
[6]  
Maehara S(1991)Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res 51 6110-7
[7]  
Mori-Iwamoto S(2005)Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival Mol Pharmacol 68 1636-44
[8]  
Kuramitsu Y(2007)Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo Cell Cycle 6 104-10
[9]  
Ryozawa S(2009)Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Mol Cancer Ther 8 45-54
[10]  
Taba K(2013)New perspectives of valproic acid in clinical practice Expert Opin Investig Drugs 22 1535-47